MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 36,555 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 13.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 308,551 shares of the company’s stock after acquiring an additional 36,555 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.11% of Lyell Immunopharma worth $197,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of Lyell Immunopharma during the fourth quarter worth about $527,000. Johnson & Johnson bought a new stake in shares of Lyell Immunopharma during the fourth quarter worth about $527,000. SG Americas Securities LLC increased its position in shares of Lyell Immunopharma by 102.8% during the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock worth $75,000 after acquiring an additional 59,182 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Lyell Immunopharma during the fourth quarter worth about $162,000. Finally, Geode Capital Management LLC increased its position in shares of Lyell Immunopharma by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company’s stock worth $2,648,000 after acquiring an additional 117,303 shares in the last quarter. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Stock Performance

Lyell Immunopharma stock opened at $0.41 on Monday. Lyell Immunopharma, Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $56.00. The stock has a market cap of $120.88 million, a PE ratio of -0.52 and a beta of -0.25. The firm’s 50-day simple moving average is $0.44 and its 200 day simple moving average is $0.60.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.01 million for the quarter. As a group, analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

Insider Buying and Selling

In other news, Director Sumant Ramachandra purchased 200,000 shares of the business’s stock in a transaction that occurred on Friday, March 21st. The shares were acquired at an average cost of $0.58 per share, for a total transaction of $116,000.00. Following the completion of the acquisition, the director now owns 200,000 shares in the company, valued at $116,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Lynn Seely bought 175,000 shares of the company’s stock in a transaction on Friday, March 14th. The stock was bought at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the completion of the purchase, the chief executive officer now owns 712,500 shares of the company’s stock, valued at approximately $434,625. The trade was a 32.56% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 768,640 shares of company stock worth $449,508. 25.10% of the stock is owned by insiders.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.